Mobixafor is a bicyclam derivative, a selective reversible antagonist of the CXCR4 chemokine receptor and blocks binding of its cognate ligand, stromal cell-derived factor-1 (SDF-1), also known as CXCL 12. Mobixafor-induced leucocytosis and elevations in circulating hematopoietic progenitor cell levels are thought to result from a disruption of CXCR4 binding to its cognate ligand, resulting in the appearance of both; mature and pluripotent cells in the systemic circulation. CD34+ cells mobilized by Mobixafor are functional and capable of engraftment with long-term repopulating capabilities.
- Adult patients – Mobixafor is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly
- Paediatric patients (1 to less than 18 years) – Mobixafor is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells
to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:
-> Pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or
-> Who previously failed to collect enough haematopoietic stem cells
- Store at 25°C, excursions permitted to 15-30°C
36 months from the date of manufacturing